Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy

Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals

(2015) Qiang Dang et al.   Molecular Oncology

Aggressive Variants of Castration-Resistant Prostate Cancer

(2014) H. Beltran et al.   CLINICAL CANCER RESEARCH

Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone

(2014) Salvatore Luca Burgio et al.   ENDOCRINE-RELATED CANCER

Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis—A Systematic Review and Pooled Analysis

(2014) Hai Tao Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

(2014) Vincenza Conteduca et al.   PROSTATE

High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

(2013) D. Lin et al.   CANCER RESEARCH

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone- und Cabazitaxel-Härtefallprogramm

(2012) M.M. Heck et al.   UROLOGE

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Therapies for Castration-Resistant Prostate Cancer

(2010) Dan L. Longo   NEW ENGLAND JOURNAL OF MEDICINE

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY